. home.aspx

NEWS

home.aspx
   


Vertex to acquire Concert Pharmaceuticals’ cystic fibrosis drug for $250m

March 07, 2017 / pharmaceutical technology
SHARESHARESHARE

US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for up to $250m.